Leslie Aden, MD
Ophthalmology · Flowood, MSNPI 1700805363
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Alcon accounts for 86.1% of it on its own, with 20 other manufacturers making up the rest. Among ophthalmology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $111.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$33K
- Glaukos Corporation$3K
- Bausch & Lomb Americas Inc.$503
- AbbVie$486
- Oyster Point Pharma, Inc.$207
- Bausch & Lomb, A Division Of Bausch Health US, LLC$200
- plus $791 from 15 others
What the payments were for
- Consulting fees$20,45054%
- Speaking & faculty fees$3,0008%
- Food & beverage$14,38638%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 224 | $32,584 |
| Glaukos Corporation | 5 | $3,065 |
| Bausch & Lomb Americas Inc. | 26 | $503 |
| AbbVie(2 entities) | 28 | $486 |
| Oyster Point Pharma, Inc. | 9 | $207 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $200 |
| NEW World Medical,inc. | 2 | $165 |
| Thea Pharma Inc. | 5 | $99 |
| Mallinckrodt Hospital Products Inc. | 4 | $97 |
| Aerie Pharmaceuticals, Inc. | 5 | $84 |
| Sun Pharmaceutical Industries Inc. | 4 | $72 |
| Biotissue Holdings Inc. | 3 | $53 |
| Ocular Therapeutix, Inc. | 2 | $45 |
| Kala Pharmaceuticals, Inc. | 3 | $40 |
| Shire North American Group Inc | 2 | $30 |
| Eyepoint US, Inc. | 1 | $20 |
| Sight Sciences, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Novartis | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$12,139
- ORA System VerifEye$9,760
- ORA$9,065
- iStent inject Trabecular Micro-Bypass Stent System$3,000
- Clareon$1,311
- AcrySof$729
- AcrySof IQ PanOptix UV IOL$501
- AcrySof IQ PanOptix$471
- ARGOS$433
- Centurion$279
- Clareon PanOptix Pro$270
- Kahook Dual Blade$150
- Streamline Surgical System$150
- Ahmed Glaucoma Valve$150
- Unity$128
- Acrysof IQ ReSTOR IOL$125
- VYZULTA$111
How this compares
$37,836 in reported general payments places this provider in the 95th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 318 | $104,882 |
| LumiganBimatoprost | 203 | $99,027 |
| Lotemax SmLoteprednol Etabonate | 391 | $95,289 |
| RestasisCyclosporine | 82 | $75,975 |
| CombiganBrimonidine Tartrate/Timolol | 67 | $29,625 |
| MoxifloxacinMoxifloxacin Hcl | 1,184 | $22,182 |
| XiidraLifitegrast | 15 | $12,695 |
| Latanoprost | 1,061 | $10,842 |
| Travoprost | 58 | $10,644 |
| VyzultaLatanoprostene Bunod | 19 | $7,710 |
| Cyclosporine | 15 | $6,322 |
| Brimonidine Tartrate | 139 | $5,319 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $4,689 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $4,445 |
| Brinzolamide | 13 | $3,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $486 | $204,628352 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate | $200 | $202,222722 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $503 | $20,40534 claims |
| AlconSimbrinza | $32,584 | $4,44522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Flowood
- Marc RichardsonFlowood$6K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Adam QuinnHattiesburg$29K
- Mark KoskoJackson$27K
- James ShippOxford$21K
- Calvin BrownOlive Branch$15K
- William AshfordMadison$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.